Longeveron LLC is a leading global regenerative medicine company developing innovative stem cell treatments that target chronic and life-threatening diseases. Through its exclusive licensing arrangements, Longeveron has been able to leverage existing data from Dr. Hare’s clinic research at the University of Miami. Longeveron now is at an advanced stage relative to when it was formed, and has multiple clinical trials underway.
Formed in 2014, the company has rapidly expanded and is conducting clinical trials in several life-threatening indications considered to be large unmet medical needs:
- Hypoplastic Left Heart Syndrome (HLHS) in Newborns
- Aging Frailty
- Alzheimer’s Disease
- The Metabolic Syndrome
The Company’s most advanced investigational product candidate is Longeveron mesenchymal stem cells (LMSCs). LMSCs are derived from the bone marrow of healthy young adult donors.
Longeveron, LLC has been able to support their rapid expansion and clinical trials through funding provided by MSCRF.
MSCRF/TEDCO support is critical to advancing these clinical initiatives. The Maryland Stem Cell Fund is one of the nation’s public leaders in advancing regenerative medicine. Working with MSCRF has enabled Longeveron to partner with experts at prestigious institutions including University of Maryland and Johns Hopkins University for the purpose of supporting the ongoing HLHS clinical trial.